Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial

Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: a randomized trial

•Single-dose BNT162b2 generated robust NAb in previously infected SARS-CoV-2 cases•Single-dose ChAdOx1 nCoV-19 also generated robust NAb in previously infected cases•Both NAb titers were similar to those induced by three doses of COVID-19 vaccines•T-Cell responses were also generated against SARS-Co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection 2022-10, Vol.85 (4), p.436-480
Hauptverfasser: Niyomnaitham, Suvimol, Toh, Zheng Quan, Licciardi, Paul Vincent, Wongprompitak, Patimaporn, Srisutthisamphan, Kanjana, Copeland, Katherine Kradangna, Chokephaibulkit, Kulkanya
Format: Artikel
Sprache:eng
Schlagworte:
COVID-19 Vaccine
Hybrid Immunity
Immunogenicity
Letter to the Editor
SARS-CoV-2
Single Dose
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Single-dose BNT162b2 generated robust NAb in previously infected SARS-CoV-2 cases•Single-dose ChAdOx1 nCoV-19 also generated robust NAb in previously infected cases•Both NAb titers were similar to those induced by three doses of COVID-19 vaccines•T-Cell responses were also generated against SARS-CoV-2 Spike protein•Both regimens provided similar protection to three doses regimens against Omicron
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2022.06.014